K
Kenvue Inc.
KVUE · Consumer Defensive
Q4 FY2025
Earning ended Dec 28, 2025Report generated Mar 10, 2026
Iconic Brands, Fading Growth Engine, and a Spinoff Hangover
Most investors see the Tylenol and Band-Aid names and assume this is a sleepy-but-safe compounder trading at a discount — the second-level reality is that two of three business segments are either flat or structurally impaired, the company was debt-loaded before it could make a single independent capital allocation decision, and the management team is simultaneously restructuring operations, conducting a strategic review, and trying to arrest organic sales declines, all at once.
Flowly Score
Apr 16 Close
+43%$17.46
Fair Value
$25.01
49
Below Averageat $17.46
Business Strength6/10
The brand portfolio is genuinely durable in OTC health — Tylenol and Listerine occupy psychological real estate that private label can't easily colonize — but the Skin Health segment is structurally different and losing ground fast, and a debt-burdened spinoff structure with a management team still building its standalone capabilities caps this at slightly above average. The moat is real, widening in some places, and quietly narrowing in others.
Financial Resilience5/10
The cash generation is genuine — OCF consistently beats net income, confirming the brands produce real cash rather than accounting constructs — but the post-spinoff debt load sitting well above a year's worth of free cash flow, combined with an Altman Z in the grey zone, means this business has limited balance sheet flexibility exactly when it needs optionality to navigate a strategic review and structural headwinds simultaneously.
Growth & Trajectory3/10
Four years of essentially flat revenue culminating in an actual organic decline is not a narrative about 'lapping tough comps' — it's a business that has stopped growing, and the Q2 2025 management admission of 'self-induced complexity' and 'unacceptable performance' signals that operational execution is compounding the problem on top of the secular headwinds. The trajectory arrow is pointing down, not sideways.
Valuation7/10at $18.16
The current price sits meaningfully below the neutral DCF fair value, which itself assumes almost no real growth — meaning you're not paying for optimism, just for the cash the brands reliably generate today. The FCF yield provides a genuine margin of safety, but the discount exists for reasons that won't self-correct without a strategic catalyst, so the gap between price and value isn't free money.
Risk4/10
The risks here are concrete and converging rather than theoretical: GLP-1 drugs quietly reducing demand in pain, digestive, and metabolic categories; private label narrowing the premium consumers will pay for Tylenol; Skin Health losing its dermatologist-recommendation moat to nimbler competitors; a strategic review whose outcome is genuinely uncertain; and a heavy debt load limiting the ability to defend or reinvest when any of these headwinds accelerate.
The investment case rests on a real foundation: a portfolio of category-defining brands that generate honest free cash flow, priced today below what a conservative no-growth DCF says they're worth. That's not nothing. For a patient investor who can stomach the near-term noise of the strategic review and accept low-to-no organic growth, the FCF yield provides genuine compensation while you wait for the discount to close. The brand equity in OTC health specifically — Tylenol, Listerine, Band-Aid — is durable in a way that makes the current price look like it over-discounts the downside. But where this business is heading is genuinely uncertain in a way the brand names obscure. The Self Care segment faces a quiet secular threat from GLP-1 adoption that won't show up in quarterly numbers until it suddenly does. The Skin Health segment is not just having a bad year — it has structurally lost the dermatologist-recommendation signal that was its primary differentiation, and no amount of marketing spend recovers that once a competitor has colonized the same credentialing system. The revenue growth rate for a business of this quality should be at least nominal; four years of flatness followed by actual decline is a business telling you something important about its competitive positioning. The single most dangerous specific risk is the Skin Health and Beauty segment entering permanent structural decline rather than cyclical weakness. If Neutrogena and Aveeno continue losing share to dermatology-backed brands and Korean skincare challengers, the overall portfolio math shifts — the segment that was supposed to carry higher growth and justify the consolidated multiple becomes a drag, and the pessimistic DCF scenario stops being a tail risk and becomes the base case. That outcome would mean the current 'discount' is not a margin of safety but a rational re-rating of a portfolio losing one of its three legs.